TAM
YMAB

Tucker Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Tucker Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,200
Closed -$19.5K – 1805
2024
Q1 		$19.5K Buy
+1,200
New +$16.2K ﹤0.01% 681

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Tucker Asset Management's YMAB Position: Q2 2024 in Review

Tucker Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q2 2024, closing a stake of 1,200 shares — an estimated $19.5K sold.

Tucker Asset Management first reported a position in YMAB in Q1 2024 and held it in 1 quarter. The position peaked at $19.5K in Q1 2024. 96 funds tracked by Wall St. Rank hold YMAB as of Q2 2024.

  • Tucker Asset Management reported no remaining Y-mAbs Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Tucker Asset Management sold 1,200 Y-mAbs Therapeutics shares in Q2 2024, an estimated $19.5K.
  • Tucker Asset Management first reported a position in Y-mAbs Therapeutics in Q1 2024 and held it in 1 quarter.
  • Tucker Asset Management's Y-mAbs Therapeutics position peaked at $19.5K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2024.

Based on Tucker Asset Management's 13F filing for Q2 2024, filed 9 Aug 2024.